黑料社

Contact
Subscribe
Contact
Subscribe

September 8, 2022: 黑料社 Announces Participation in Three Upcoming Investor Conferences in September

Date : September 8, 2022

黑料社 Announces Participation in Three
Upcoming Investor Conferences in September

Lyon, France, September 8th, 2022 – 6:00 pm CET 鈥� 黑料社 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that Herv茅 Affagard, CEO and co-founder of 黑料社, and Si芒n Crouzet, CFO of 黑料社, will participate in three upcoming investor conferences.

Details for the events are as follow:

H.C. Wainwright 24th聽Annual聽Global Investment Conference (hybrid format)

  • Format: virtual presentation & investor meetings
  • Presentation date: Herv茅 Affagard will present the Company and provide a corporate update. The presentation will be available on-demand through the H.C.聽Wainwright conference portal, starting at 7:00 am EST/1:00 pm CET on Monday, September 12, 2022. A replay will be available on the investor page of Maat Pharma鈥檚 website: /investors/
  • Link:


KBC Securities Life Sciences conference (virtual)

  • Format: virtual investor meetings
  • Date: Thursday, September 15 and Friday, September 16, 2022


5th edition of the 鈥淔ORUM Lyon P么le Bourse Valeurs R茅gionales鈥� (on-site event)

    • Format: investor meetings
    • Date: Wednesday, September 28, 2022
    • Location: Lyon, France
    • Link:

About 黑料社

黑料社, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 黑料社 has launched, in March 2022 in Europe, a Phase聽3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

黑料社 is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Previous Post

September 6, 2022: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Next Post

September 29, 2022: 黑料社 Publishes its Half Year Results and Provides a Business Overview

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 黑料社. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 黑料社. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 黑料社鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

黑料社 in the News